Liquidia Corp - רווח למניה לשנה מתגלגלת LQDA

The stability of Liquidia Corporation (LQDA) is guaranteed by the non-cyclical nature of pulmonary hypertension therapy, which eliminates the impact of crises. The historical YoY TTM EPS delta confirms this resilience, where 27.40 becomes the new value for this metric. Growth is driven by innovative powder inhalers that simplify treatment. Currently, Liquidia Corporation (LQDA) is focusing on independently bringing products to market, refining only the technological aspects of drug delivery.
liquidia.com - פילוחים אנליטיים ומדדי מפתח (LQDA)

This indicator reflects the rate of change in net income per share over the last twelve months, allowing for an assessment of the business's actual operating efficiency relative to the industry benchmark. By analyzing the TTM annual net income per share dynamics, an investor can discern the financial stability of Liquidia Corporation (LQDA), whose market capitalization depends directly on the success of multi-year patent developments and the overcoming of regulatory barriers.